广州医科大学学报
廣州醫科大學學報
엄주의과대학학보
Academic Journal of Guangzhou Medical College
2015年
4期
31-33,44
,共4页
胡中伟%柯娥%黄春明%郭家伟%詹远京%欧志涛
鬍中偉%柯娥%黃春明%郭傢偉%詹遠京%歐誌濤
호중위%가아%황춘명%곽가위%첨원경%구지도
非酒精性脂肪肝%ω-3多不饱和脂肪酸%病理学%血脂
非酒精性脂肪肝%ω-3多不飽和脂肪痠%病理學%血脂
비주정성지방간%ω-3다불포화지방산%병이학%혈지
non-alcoholic fatty liver%ω-3 polyunsaturated fatty acids%pathology%blood lipid
目的：：评估海狗油ω-3多不饱和脂肪酸胶丸治疗非酒精性脂肪肝( NAFLD)的临床效果。方法：将2007年1月至2013年1月广州医科大学附属市第八人民医院收治的43例NAFLD患者随机分为试验组(26例)和对照组(17例)，试验组服用海狗油ω-3多不饱和脂肪酸胶丸，对照组服用安慰剂，共24周。对比治疗前后病理分级、B超评分及丙氨酸基转移酶( ALT)、天冬氨酸氨基转移酶( AST)、体质量指数( BMI)、甘油三酯( TG)、总胆固醇( TC)、胰岛素抵抗指数( HOMA-IR)等指标差异。结果：经24周治疗后，试验组B超评分、TG、BMI、HOMA-IR较治疗前明显降低(P<0.05)，与对照组比较也明显较低(P<0.05)。两组肝脂肪变程度、炎症、纤维化、ALT、AST、TC比较，差异无统计学意义(P>0.05)。结论：海狗油ω-3多不饱和脂肪酸胶丸能降低NAFLD患者TG、BMI、HOMA-IR水平，改善脂肪肝B超分级，但与病理组织学改变的关系不明显。
目的：：評估海狗油ω-3多不飽和脂肪痠膠汍治療非酒精性脂肪肝( NAFLD)的臨床效果。方法：將2007年1月至2013年1月廣州醫科大學附屬市第八人民醫院收治的43例NAFLD患者隨機分為試驗組(26例)和對照組(17例)，試驗組服用海狗油ω-3多不飽和脂肪痠膠汍，對照組服用安慰劑，共24週。對比治療前後病理分級、B超評分及丙氨痠基轉移酶( ALT)、天鼕氨痠氨基轉移酶( AST)、體質量指數( BMI)、甘油三酯( TG)、總膽固醇( TC)、胰島素牴抗指數( HOMA-IR)等指標差異。結果：經24週治療後，試驗組B超評分、TG、BMI、HOMA-IR較治療前明顯降低(P<0.05)，與對照組比較也明顯較低(P<0.05)。兩組肝脂肪變程度、炎癥、纖維化、ALT、AST、TC比較，差異無統計學意義(P>0.05)。結論：海狗油ω-3多不飽和脂肪痠膠汍能降低NAFLD患者TG、BMI、HOMA-IR水平，改善脂肪肝B超分級，但與病理組織學改變的關繫不明顯。
목적：：평고해구유ω-3다불포화지방산효환치료비주정성지방간( NAFLD)적림상효과。방법：장2007년1월지2013년1월엄주의과대학부속시제팔인민의원수치적43례NAFLD환자수궤분위시험조(26례)화대조조(17례)，시험조복용해구유ω-3다불포화지방산효환，대조조복용안위제，공24주。대비치료전후병리분급、B초평분급병안산기전이매( ALT)、천동안산안기전이매( AST)、체질량지수( BMI)、감유삼지( TG)、총담고순( TC)、이도소저항지수( HOMA-IR)등지표차이。결과：경24주치료후，시험조B초평분、TG、BMI、HOMA-IR교치료전명현강저(P<0.05)，여대조조비교야명현교저(P<0.05)。량조간지방변정도、염증、섬유화、ALT、AST、TC비교，차이무통계학의의(P>0.05)。결론：해구유ω-3다불포화지방산효환능강저NAFLD환자TG、BMI、HOMA-IR수평，개선지방간B초분급，단여병리조직학개변적관계불명현。
Objective:To assess the therapeutic effect ofω-3 polyunsaturated fatty acids ( PUFA) of seal oil on non-alcoholic fatty liver disease ( NAFLD ) . Methods: Forty-three patients with NAFLD, who were hospitalized in Eighth Municipal People′s Hospital Affiliated to Guangzhou Medical University between January 2007 and January 2013, were randomly divided into the study group ( n=26) and control group ( n=17) . The study group was given seal oilω-3 PUFA soft capsule and the control group was given placebo for 24 weeks. The differences of pathological grade, ultrasound scores, alanine aminotransferase ( ALT ) , aspartate transaminase (AST), body mass index (BMI), triglyceride (TG), total cholesterol (TC), insulin resistance (HOMA-IR) index in two groups were compared before and after the treatment. Results:The ultrasound scores, TG, BMI and HOMA-IR were significantly decreased after 24-week treatment compared with those before the treatment in the study group ( P<0.05) , which were significantly decreased compared with those in the control group ( P<0. 05) . There were no statistically significant differences in the fatty liver disease pathological change, inflammation, fibrosis, ALT, AST and TC between two groups (P>0.05). Conclusion: Seal oil ω-3 PUFA soft capsule can decrease TG, BMI and HOMA-IR levels, and improve fatty liver ultrasound grade in NAFLD patients, without significant correlation with the changes of pathologic histology.
